Palvella Therapeutics Inc. (NASDAQ: PVLA) announced that two abstracts highlighting results from Phase 3 SELVA and Phase 2 TOIVA studies ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE